Eurofins Discovery

Human iPSC-derived cardiomyocytes for cardiac proarrhythmic risk assessment

27 October 2021 | By Anton Simeonov, Drug Target Review, Victoria Rees (Drug Target Review)

Following Drug Target Review's webinar supported by Eurofins, speaker Dr Verena Albert answers the questions posed by the audience during the live event.

Flyer: Introducing Eurofins Beacon Discovery; the GPCR experts

17 September 2021 | By Eurofins Discovery

Learn how you can partner for success with Eurofins Beacon Discovery’s industry leading GPCR experts to support your program from concept to clinic.

Cardiac proarrhythmic risk assessment using human-induced pluripotent stem cell-derived cardiomyocytes

19 August 2021 | By Eurofins Discovery

Watch this on-demand webinar that discusses the two assays developed by Eurofins and why they represent a more physiologic and dynamic system to provide a more comprehensive pre-clinical model for cardiac liability assessment.

Automating functional cell-based bioassays: assay reproducibility and performance for potency testing programmes

28 May 2021 | By Eurofins DiscoverX* and Tecan

In this on-demand webinar, we discuss how Eurofins DiscoverX’s off-the-shelf, MOA-based functional, cellular assays address these challenges, enabling drug discovery programmes up to late-stage development and market release.

Hit discovery for GPCRs: HTS or virtual screens?

8 April 2021 | By Beacon Discovery

Watch our on-demand webinar and learn from an industry expert regarding GPCR virtual screening approaches and challenges and much more.

Paradigm Shift in Drug Discovery: Discover Small Molecule Degraders Using E3scan™ Technology Platform

4 March 2021 | By Eurofins Discovery

Book your place for our free webinar and learn about how targeted protein degradation (TPD) utilises small molecules to hijack the cellular degradation machinery through the recruitment of E3 ubiquitin ligases to proteins of interest.

Whitepaper: Biomarkers and mechanisms of toxicity

23 February 2021 | By Eurofins Discovery

Phenotypic profiling identifies biomarkers and mechanisms of toxicity.

Whitepaper: Profiling oncology candidates

9 February 2021 | By Eurofins Discovery

Profiling oncology drug candidates through complementary in vitro assays and in vivo models to better understand their potential clinical applications.

Novel small molecule inhibitors of oncogenic SHP2 variants characterised by cellular target engagement

28 January 2021 | By Eurofins DiscoverX & Sanford Burnham Prebys Discovery

In this on-demand webinar industry experts discuss how the InCELL Pulse technology provides a valuable tool for the discovery and characterisation of novel SHP2 inhibitors.

Case study: Identifying allosteric modulators for GPCRs

25 January 2021 | By Eurofins Discovery

Identifying allosteric modulators and biased agonists for clinically relevant GPCRs. Case Studies using Eurofins Discovery’s GPCR product solutions.

Eurofins Discovery

Using bioactivity profiling to support the progression of phenotypic hits

7 September 2018 | By DiscoverX Corporation, Eurofins Pharma Discovery Services

This webinar, held on 28 June 2018, illustrated the optimisation of hits derived from a target-agnostic phenotypic screen, using a strategy based on combining bioactivity profiling and reference compound characterisation. Keynote speaker Arsenio Nueda, Head of Molecular Biology at Almirall, responded as follows to questions posed during the webinar.

Bioactivity profiling supporting the progression of phenotypic hits

22 June 2018 | By Drug Target Review

Addressing the optimisation of hits derived from a target-agnostic phenotypic screen, using a strategy based on combining bioactivity profiling and reference compound characterisation...

Supporting the progression of phenotypic hits with bioactivity profiling

4 June 2018 | By Drug Target Review

Bioactivity profiling has been traditionally used to assess the selectivity of new drug candidates in the context of target-based approaches, where pharmacological selectivity is a key requirement.

Using bioactivity profiling to support the progression of phenotypic hits

27 April 2018 | By Eurofins Pharma Discovery Services

In this webinar, we discussed a recent case study where a phenotypic screen was performed using poly I:C / IL-4 stimulated human bronchial epithelial cells. This resulted in the identification of 7 representative hits which provided starting points for new drug discovery opportunities.